US FDA flags manufacturing and data integrity lapses at Dabur India plant

The U.S. Food and Drug Administration has just delivered a scathing Form 483 to Dabur India, detailing egregious manufacturing and data integrity lapses at one of its key facilities near Ghaziabad. Inspectors reportedly found a live bird, extensive bird droppings, and "unidentified black substances" in storage areas, directly compromising the sterile environment required for consumer health products. This immediate flag raises serious concerns about the safety and efficacy of products destined for the crucial U.S. market, particularly those marketed under its rapidly expanding Ayurvedic portfolio. This isn't just a compliance hiccup; it's a stark reminder of the escalating global scrutiny on Indian manufacturers, amplified post-pandemic by supply chain vulnerabilities and renewed regulatory vigilance. The FDA's report explicitly questioned the reliability of Dabur's microbiological testing, observing contamination in samples that had mysteriously "passed" internal safety checks—a direct challenge to the company's data integrity. This follows a pattern of heightened regulatory action across the Indian pharmaceutical and consumer goods sector, putting pressure on companies like Dabur to modernize facilities and adhere to international Good Manufacturing Practices (GMP) beyond domestic standards. Dabur now faces a tight deadline to respond with a robust plan for Corrective and Preventive Actions (CAPA), a process the FDA will closely monitor. Failure to adequately address these severe observations could swiftly escalate to a formal Warning Letter or even an Import Alert, effectively barring specific products from U.S. entry—a significant blow to Dabur's international ambitions and stock performance. Investors will be watching closely for how swiftly and transparently Dabur moves to regain trust and demonstrate ironclad quality control.